GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated January 2, 2024, serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R. The report details the company's issued share capital and total voting rights as of December 31, 2023.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
Material Changes
The filing does not disclose material changes in financial performance compared to prior periods. It reports the static capital position as of the end of 2023.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. Its sole purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under FCA rules.
Key Facts for Investors
- Issued Share Capital: As of December 31, 2023, GSK Plc had 4,312,145,983 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 197,068,169 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,115,077,814.
- Regulatory Use: Shareholders must use the total voting rights figure (4,115,077,814) as the denominator to determine if they are required to notify their interest or changes in interest under FCA rules.